Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc. (NASDAQ:MRNA)’s refrigerator-stable COVID-19 vaccine, Brookline Capital Markets reaffirmed its Buy rating and $198 price target for the company on September 23.
Photo by Ian Hutchinson on Unsplash
According to the new data, mNEXSPIKE/mRNA-1283 increased neutralizing antibodies against the LP.8.1 variant by an average of more than sixteen times, which Brookline regarded as “remarkably strong” when compared with Moderna’s initial COVID-19 vaccination and phase III registration results.
Brookline predicts that Moderna’s COVID-19 vaccine sales will total 10.9 million units in the United States this year, down from an expected 14.6 million in 2024, with possible global sales of $2.1 billion in 2025 and $15.6 billion by 2030.
Moderna, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of mRNA-based medicines and vaccines. The company received solid recognition for its COVID-19 vaccine, which was one of the first mRNA vaccines to be created and delivered worldwide.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
